Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load

Antoine Leuzy, PhD,* Johan Lilja, PhD,* Christopher J. Buckley, PhD, Rik Ossenkoppele, PhD, Sebastian Palmqvist, MD, PhD, Mark Battle, MSc, Gill Farrar, PhD, Dietmar R. Thal, MD, Shorenna Janelidze, PhD, Erik Stomrud, MD, PhD, Olof Strandberg, PhD, Ruben Smith, MD, PhD, and Oskar Hansson, MD, PhD

Neurology® 2020;95:e2834-e2844. doi:10.1212/WNL.0000000000011031

Abstract

Objective
To evaluate a novel β-amyloid (Aβ)-PET–based quantitative measure (Aβ accumulation index [Aβ index]), including the assessment of its ability to discriminate between participants based on Aβ status using visual read, CSF Aβ42/Aβ40, and post-mortem neuritic plaque burden as standards of truth.

Methods
One thousand one hundred twenty-one participants (with and without cognitive impairment) were scanned with Aβ-PET: Swedish BioFINDER, n = 392, [18F]flutemetamol; Alzheimer’s Disease Neuroimaging Initiative (ADNI), n = 692, [18F]florbetapir; and a phase 3 end-of-life study, n = 100, [18F]flutemetamol. The relationships between Aβ index and standardized uptake values ratios (SUVR) from Aβ-PET were assessed. The diagnostic performances of Aβ index and SUVR were compared with visual reads, CSF Aβ42/Aβ40, and Aβ histopathology used as reference standards.

Results
Strong associations were observed between Aβ index and SUVR (R²: BioFINDER 0.951, ADNI 0.943, end-of-life, 0.916). Both measures performed equally well in differentiating Aβ-positive from Aβ-negative participants, with areas under the curve (AUCs) of 0.979 to 0.991 to detect abnormal visual reads, AUCs of 0.961 to 0.966 to detect abnormal CSF Aβ42/Aβ40, and AUCs of 0.820 to 0.823 to detect abnormal Aβ histopathology. Both measures also showed a similar distribution across postmortem-based Aβ phases (based on anti-Aβ 4G8 antibodies). Compared to models using visual read alone, the addition of the Aβ index resulted in a significant increase in AUC and a decrease in Akaike information criterion to detect abnormal Aβ histopathology.

Conclusion
The proposed Aβ index showed a tight association to SUVR and carries an advantage over the latter in that it does not require the definition of regions of interest or the use of MRI. Aβ index may thus prove simpler to implement in clinical settings and may also facilitate the comparison of findings using different Aβ-PET tracers.

Classification of evidence
This study provides Class III evidence that the Aβ accumulation index accurately differentiates Aβ-positive from Aβ-negative participants compared to Aβ-PET visual reads, CSF Aβ42/Aβ40, and Aβ histopathology.

*These authors contributed equally to this work.

From the Clinical Memory Research Unit (A.L., J.L., R.O., S.P., S.J., E.S., O.S., O.H.), Department of Clinical Sciences, Lund University, Malmö; Department of Surgical Sciences, Nuclear Medicine and PET (J.L.), Uppsala University; Hermes Medical Solutions (J.L.), Stockholm, Sweden; GE Healthcare Life Sciences (C.J.B., M.B., G.F.), Amersham, UK; VU University Medical Center (R.O.), Neuroscience Campus Amsterdam, the Netherlands; Department of Neurology (S.P., R.S.) and Memory Clinic (E.S., O.H.), Skåne University Hospital, Lund, Sweden; Department of Imaging and Pathology (D.R.T.), Laboratory of Neuropathology, and Leuven Brain Institute (D.R.T.), Campus Gasthuisberg; and Department of Pathology (D.R.T.), UZ-Leuven, Belgium.

Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
β-Amyloid (Aβ)-PET tracers such as [18F]flutemetamol are currently approved for visual assessment only (whereby images are rated as negative/positive (normal/abnormal) by a trained rater).1,2 Evidence suggests, however, that quantifying the amount of tracer retention in the brain may improve agreement between raters3 and aid in the monitoring of treatment effects in anti-Aβ trials.4 The most commonly used quantitative measure for Aβ-PET is the standardized uptake value ratio (SUVR), in which tracer concentration in cortical (target) regions is divided by that within a reference region of interest (ROIs), this technique is not always available in clinical settings and is frequently contraindicated in elderly patients.5

In the absence of MRI, PET-only approaches can be used.6 In this approach, a PET image is first transformed from a standardized coordinate space (spatial normalization), and ROIs are then defined with a probabilistic atlas. Using such an approach, we recently described a novel measure of brain Aβ burden (Aβ index).7 Because it does not require the definition of ROIs, it is simpler to implement than SUVR. Here, we aimed (1) to compare Aβ index and SUVR in 3 independent cohorts; (2) to assess their ability to differentiate Aβ-positive and Aβ-negative participants using visual read, CSF Aβ42/Aβ40 or postmortem neuritic plaque burden as standards of truth; and (3) to assess whether a combination of visual read and Aβ index was superior to visual read alone to predict Aβ positivity using CSF Aβ42/Aβ40 and postmortem neuritic plaque burden as standards of truth. We hypothesized that across these aims, Aβ index would show noninferiority to SUVR.

Methods

Participants

Our population consisted of 1,121 participants with Aβ-PET from 3 separate cohorts: 392 from the Swedish BioFINDER study (clinical trial no. NCT01208675), scanned with [18F] flutemetamol (251 cognitively unimpaired [CU], including 129 elderly controls, 122 with subjective cognitive decline, and 141 cognitively impaired [CI] participants with mild cognitive impairment), 629 from the Swedish BioFINDER (clinical trial Nos. NCT01165554 and NCT02090855) who were scanned with [18F]flutemetamol antemortem and autopsied after death.8-10 Inclusion criteria for CU and CI individuals from BioFINDER and ADNI have been described elsewhere11,12 and are described in the supplement (appendices e-1 and e-2, doi:10.5061/dryad.2547d7wnf). In the end-of-life study, participants were ≥55 years of age, terminally ill with a life expectancy <3 years, and with general health sufficient to allow completion of study procedures. Dementia, defined according to the DSM-IV criteria, was noted as present or absent, as reported in case notes. The relationship between Aβ index and SUVR was also examined in patients with Alzheimer disease (AD) dementia with CSF Aβ42/Aβ40 used as the standard of truth for Aβ status (BioFINDER, n = 25 with [18F]flutemetamol PET available and n = 25 from ADNI with [18F]florbetapir).

Standard protocol approvals, registrations, and patient consents

Written informed consent was obtained from all patients (or guardians of patients) participating in the study (consent for research). Ethics approval for BioFINDER was given by the Regional Ethical Committee of Lund University. Approval for PET imaging was obtained from the Swedish Medical Products Agency and the local Radiation Safety Committee at Skåne University Hospital. For the ADNI and end-of-life cohorts, study protocols were approved by local ethical committees.

Image acquisition and processing

For BioFINDER, [18F]flutemetamol studies were performed with a Philips Gemini TF PET/CT scanner (Philips Medical Systems, Amsterdam, the Netherlands) over the interval of 90 to 110 minutes after injection; data were acquired in list mode and binned into frames with an iterative Vue Point HD algorithm (6 subsets, 18 iterations with 3-mm filter and no time-of-flight correction). All participants underwent 3T MRI scans (Siemens MAGNETOM Prisma, Munich, Germany), acquiring isometric 1-mm3 T1-weighted magnetization-prepared rapid gradient echo images. For ADNI, [18F]florbetapir image data acquired 50 to 70 minutes after injection13 and T1-weighted MRI scans using a sagittal volumetric magnetization-prepared rapid gradient echo sequence acquired at 3T were used.14 For the phase 3 end-of-life study, [18F]flutemetamol PET images were acquired on PET/CT cameras over the interval of 90 to 110 minutes after injection. Because both ADNI and the phase 3 end-of-life study were multicentric in nature, images were smoothed to achieve a uniform imaging resolution.

Glossary

Aβ = β-amyloid; AD = Alzheimer disease; ADNI = Alzheimer’s Disease Neuroimaging Initiative; AIC = Akaike information criterion; AUC = area under the curve; CERAD = Consortium to Establish a Registry for Alzheimer’s Disease; CI = cognitively impaired; CU = cognitively unimpaired; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, 4th edition; ROI = region of interest; SUVR = standardized uptake value ratio.

β-Amyloid (Aβ)-PET tracers such as [18F]flutemetamol are currently approved for visual assessment only (whereby images are rated as negative/positive (normal/abnormal) by a trained rater).1,2 Evidence suggests, however, that quantifying the amount of tracer retention in the brain may improve agreement between raters3 and aid in the monitoring of treatment effects in anti-Aβ trials.4 The most commonly used quantitative measure for Aβ-PET is the standardized uptake value ratio (SUVR), in which tracer concentration in cortical (target) regions is divided by that within a reference region of interest (ROIs), this technique is not always available in clinical settings and is frequently contraindicated in elderly patients.5

In the absence of MRI, PET-only approaches can be used.6 In this approach, a PET image is first transformed from a standardized coordinate space (spatial normalization), and ROIs are then defined with a probabilistic atlas. Using such an approach, we recently described a novel measure of brain Aβ burden (Aβ index).7 Because it does not require the definition of ROIs, it is simpler to implement than SUVR. Here, we aimed (1) to compare Aβ index and SUVR in 3 independent cohorts; (2) to assess their ability to differentiate Aβ-positive and Aβ-negative participants using visual read, CSF Aβ42/Aβ40 or postmortem neuritic plaque burden as standards of truth; and (3) to assess whether a combination of visual read and Aβ index was superior to visual read alone to predict Aβ positivity using CSF Aβ42/Aβ40 and postmortem neuritic plaque burden as standards of truth. We hypothesized that across these aims, Aβ index would show noninferiority to SUVR.

Methods

Participants

Our population consisted of 1,121 participants with Aβ-PET from 3 separate cohorts: 392 from the Swedish BioFINDER study (clinical trial no. NCT01208675), scanned with [18F] flutemetamol (251 cognitively unimpaired [CU], including 129 elderly controls, 122 with subjective cognitive decline, and 141 cognitively impaired [CI] participants with mild cognitive impairment), 629 from the Swedish BioFINDER (clinical trial Nos. NCT01165554 and NCT02090855) who were scanned with [18F]flutemetamol antemortem and autopsied after death.8-10 Inclusion criteria for CU and CI individuals from BioFINDER and ADNI have been described elsewhere11,12 and are described in the supplement (appendices e-1 and e-2, doi:10.5061/dryad.2547d7wnf). In the end-of-life study, participants were ≥55 years of age, terminally ill with a life expectancy <3 years, and with general health sufficient to allow completion of study procedures. Dementia, defined according to the DSM-IV criteria, was noted as present or absent, as reported in case notes. The relationship between Aβ index and SUVR was also examined in patients with Alzheimer disease (AD) dementia with CSF Aβ42/Aβ40 used as the standard of truth for Aβ status (BioFINDER, n = 25 with [18F]flutemetamol PET available and n = 25 from ADNI with [18F]florbetapir).

Standard protocol approvals, registrations, and patient consents

Written informed consent was obtained from all patients (or guardians of patients) participating in the study (consent for research). Ethics approval for BioFINDER was given by the Regional Ethical Committee of Lund University. Approval for PET imaging was obtained from the Swedish Medical Products Agency and the local Radiation Safety Committee at Skåne University Hospital. For the ADNI and end-of-life cohorts, study protocols were approved by local ethical committees.

Image acquisition and processing

For BioFINDER, [18F]flutemetamol studies were performed with a Philips Gemini TF PET/CT scanner (Philips Medical Systems, Amsterdam, the Netherlands) over the interval of 90 to 110 minutes after injection; data were acquired in list mode and binned into frames with an iterative Vue Point HD algorithm (6 subsets, 18 iterations with 3-mm filter and no time-of-flight correction). All participants underwent 3T MRI scans (Siemens MAGNETOM Prisma, Munich, Germany), acquiring isometric 1-mm3 T1-weighted magnetization-prepared rapid gradient echo images. For ADNI, [18F]florbetapir image data acquired 50 to 70 minutes after injection13 and T1-weighted MRI scans using a sagittal volumetric magnetization-prepared rapid gradient echo sequence acquired at 3T were used.14 For the phase 3 end-of-life study, [18F]flutemetamol PET images were acquired on PET/CT cameras over the interval of 90 to 110 minutes after injection. Because both ADNI and the phase 3 end-of-life study were multicentric in nature, images were smoothed to achieve a uniform imaging resolution.
Aβ-PET images were spatially normalized with 2 approaches: an MRI-driven approach included in SPM12 and a PET-driven principal component approach. For the end-of-life cohort, normalization of [18F]flutemetamol images was performed only with the principal component approach because MRI was not available. The purpose of this dual approach was to ensure that SUVRs from the principal component approach were highly correlated with those derived with the MRI-driven gold standard approach. The complete details of the principal component approach can be found in the original publication. Briefly, tracer-specific principal component images are first calculated by singular value decomposition of Aβ-PET SUV images. Two principal components were chosen because they captured ≥95% of the variance in the dataset. The first principal component represents the average of all the images the dataset; the second, the different between Aβ-positive and Aβ-negative images (i.e., specific binding). A synthetic template (I_{synthetic}) can then be modeled as a linear combination of the first and second principal component images (I_{PC1} and I_{PC2}, respectively). As part of this operation, I_{PC2} is multiplied by a weighting factor (Aβ index; i.e., I_{synthetic} = I_{PC1} + Aβ index × I_{PC2}) representing a global measure of brain Aβ pathology. Here, a positive Aβ index yields a template with a more Aβ-positive appearance and a negative value yields a template with a more Aβ-negative appearance. With the use of an algorithm that incorporates both the Aβ index and the parameters required for the spatial transformation, the synthetic template can then be used to normalize Aβ-PET images.

In the present study, preexisting synthetic templates derived from phase 2 studies were used for [18F]flutemetamol and [18F]florbetapir. After spatial normalization of [18F]flutemetamol and [18F]florbetapir scans, 2 sets of SUVRs were calculated (one for each normalization method) for BioFINDER and ADNI participants using a composite cortical ROI—encompassing brain regions typically showing high Aβ load in AD, including frontal, temporal, and parietal cortices, precuneus, anterior striatum, and insular cortex—and the pons and cerebellum as reference tissues for [18F]flutemetamol and [18F]florbetapir, respectively. As described, SUVR values for [18F]flutemetamol scans from the end-of-life cohort were based on the principal component–based normalization alone.

The term principal component herein refers to the principal component–driven normalization approach (and, for instance, SUVR values derived from images normalized using this approach), not the Aβ index per se (which is generated when the principal component–driven approach is used for spatial normalization).

**CSF biomarkers**

Lumbar puncture and CSF handling followed structured protocols in the BioFINDER and ADNI studies. In BioFINDER, the fully automated Elecsys assays (Roche Diagnostics, Indianapolis, IN) were used, as described elsewhere, with samples analyzed at the Clinical Neurochemistry Laboratory, University of Gothenburg, Sweden. In ADNI, CSF Aβ_{42}/Aβ_{40} was determined from Aβ_{42} and Aβ_{40} measurements derived from a liquid chromatography with tandem mass spectrometry method, with samples analyzed in the Biomarker Research Laboratory, University of Pennsylvania.

**Postmortem Aβ pathology assessment**

Postmortem-base estimates of Aβ plaque pathology were based on autopsy brain tissue previously collected in support of the GE067-007/GE067-026 phase 3 clinical trials for [18F] flutemetamol PET. As described elsewhere, after formalin fixation, brains were coronally sliced and macroscopically screened. The Bielschowsky silver method was then applied to paraffin-embedded tissue from 8 neocortical regions, as defined by the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). In each region, neuritic plaque densities were recorded as 0 (no plaques), 1 (sparse; 1–5 plaques), 2 (moderate; 6–19 plaques), or 3 (frequent; >20 plaques), per 100× field of view. A modified CERAD-based assessment approach was then applied whereby the arithmetic mean of neuritic plaque density was calculated across the 8 investigated regions (30 measures per region), giving a continuous variable. Aβ phases 9 describing the hierarchical spreading of Aβ plaque pathology in the brain were determined after screening the Aβ-stained sections (anti-Aβ 4G8 antibodies) for plaque distribution.

**Definition of Aβ status**

Aβ status (positive/negative), as a standard of truth, was defined with 3 approaches: in ADNI and BioFINDER using consensus read of Aβ-PET uptake images and CSF Aβ_{42}/Aβ_{40}, and in the end-of-life trial using the postmortem–based Bielschowsky histopathology score. For CSF Aβ_{42}/Aβ_{40} cutoffs of 0.059 (BioFINDER) and 0.137 (ADNI) were used, based on gaussian mixture modeling applied to the BioFINDER and ADNI cohorts. For Bielschowsky silver stain, each assessed brain region was scored from 0 to 3 (calculated as the arithmetic mean of 30 measures); a score >1.5, previously shown to represent the threshold between the categories of sparse and moderate neuritic plaques, in any of the 8 investigated regions was considered abnormal, with the brain classified as Aβ positive.

**Statistical analyses**

Between-group characteristics were compared with the Kruskal-Wallis or Fisher exact test. The relationship between Aβ index and SUV from [18F]flutemetamol and [18F]florbetapir was examined with linear regression and coefficient of determination (R²). Receiver operating characteristic analyses were performed to generate area under the curve (AUC) values for both Aβ index and SUV. Differences in AUC values for these measures were evaluated with bootstrap (n = 1,000) procedures. To assess the added clinical value of the Aβ index, AUC and Akaike information criterion (AIC) values from binary logistic regression models (using CSF Aβ_{42}/Aβ_{40} [BioFINDER and ADNI] and Bielschowsky histopathology...
[end-of-life cohort] as the outcome variables [positive/negative]) and visual read (model 1) or visual read in combination with Aβ index (continuous, model 2) were compared. For comparison, a third model combining visual read and SUVR was included. All analyses were performed in R (version 3.5.3; R-project.org/), with significance set at p < 0.05, 2 sided.

Primary research question
The primary research question was how Aβ index and SUVR from Aβ PET compare in their ability to differentiate participants according to their Aβ status. This study provides Class III evidence that the Aβ accumulation index accurately differentiates Aβ-positive from Aβ-negative participants compared to Aβ-PET visual reads, CSF Aβ42/Aβ40, and Aβ histopathology.

Data availability
Anonymized study data for the primary analyses presented in this report are available on request from any qualified investigator for purposes of replicating the results.

| Table 1 BioFINDER and ADNI cohort characteristics |
|-----------------|-----------------|-----------------|
| Characteristic  | BioFINDER        | ADNI            |
|                 | CU CI            | CU CI           |
| No.             | 251 141          | 246 383         |
| Age, mean (SD)  | 71.92 (5.15) [59, 85] | 70.91 (5.58) [60, 80] |
| Male/female, n  | 109/142 (43)     | 121/125 (49)    |
| Education, y    | 12.17 (3.39)     | 16.82 (2.49)    |
| MMSE score      | 28.79 (1.23)     | 29.05 (1.18)    |
| APOE e4+, n (%) | 91 (36)          | 51 (28)         |
| CSF Aβ42/Aβ40+, | 71 (28)          | 71 (29)         |
| Aβ PET, visual read+, | 48 (19) | 51 (21) |
| Aβ PET, SUVR    | 0.65 (0.15)      | 1.17 (0.19)     |
| Aβ PET, Aβ index| -0.79 (0.63)     | -0.82 (0.84)    |

Abbreviations: Aβ = β-amyloid; CI = cognitively impaired; CU = cognitively unimpaired; MMSE = Mini-Mental State Examination; SUVR = standardized uptake values ratio.

| Table 2 End-of-life cohort characteristics |
|-----------------|-----------------|-----------------|
| Characteristic  | Dementia        | No dementia     | All participants |
| No.             | 85              | 15              | 100             |
| Age, mean (SD)  | 82.71 (7.91) [60, 96] | 78.40 (11.09) [60, 93] | 82.10 (8.54) [60, 96] |
| Male/female, n  | 32/53 (38)      | 5/10 (33)      | 42/58 (58)      |
| Dementia, n (%) | 85 (100)        | 0 (0)          | 85 (85)         |
| Bielschowsky silver stain | 2.00 (0.79) | 1.31 (1.13) | 1.90 (0.88) |
| Thal Aβ phase 1/2/3/4/5, n | 6/4/10/21/44 | 5/1/4/2/3 | 11/5/14/24/46 |
| Braak tau stage, I-II/III-IV-VI, n | 14/17/50 | 4/8/1 | 18/25/51 |
| CERAD, N/S/M/F, n | 4/18/26/37 | 5/1/6/2 | 9/20/32/39 |
| Aβ PET, visual read+, n (%) | 67 (79) | 5/10 (33) | 72 (72) |
| Aβ PET, SUVR    | 0.88 (0.20)     | 0.79 (0.22)    | 0.87 (0.21)    |
| Aβ PET, Aβ index| 0.31 (0.81)     | -0.19 (0.89)   | 0.23 (0.84)    |
| Scan-to-death time interval, d | 234.95 (215.48) | 234.13 (189.26) | 234.83 (210.86) |

Abbreviations: Aβ = β-amyloid; CERAD = Consortium to Establish a Registry for Alzheimer’s Disease; N/S/M/F = none/sparse/moderate/frequent; SUVR = standardized uptake values ratio.
Results

Cohort characteristics are summarized in table 1 (BioFINDER and ADNI) and table 2 (end-of-life study). Among the 85 cases in the end-of-life cohort with an antemortem diagnosis of dementia, 28 (33%) had a postmortem neuropathologic diagnosis of pure AD, 33 (39%) had a diagnosis of AD plus at least 1 other pathology (e.g., cerebral amyloid angiopathy or TAR DNA-binding protein 43), and 24 (28%) had a non-AD pathology such as Lewy body or vascular dementia. Figure 1 provides an overview of the steps required to generate the Aβ index. Principal component images for [18F]flutemetamol and [18F]florbetapir are provided in figure e-1 (doi:10.5061/dryad.2547d7wnf). Comparison of SUVR values using principal component– and MRI- (SPM12) driven normalization approaches showed good agreement (figure e-2), with R^2 values of 0.997 for [18F]flutemetamol and 0.995 for [18F]florbetapir (p < 0.001). Characteristics of AD dementia participants are summarized in table e-1.

Strong associations were observed between Aβ index– and principal component–derived SUVR values in both cohorts (BioFINDER R^2 = 0.951 [95% confidence interval 0.933–0.961], ADNI R^2 = 0.943 [95% confidence interval 0.927–0.952], p < 0.001) (figure 2). Comparison of receiver operating characteristic curve–derived AUC values from Aβ index and SUVR showed that both measures performed equally well in differentiating Aβ-positive from Aβ-negative participants, with both visual read (AUCs 0.979 [95% confidence interval 0.972–0.989]) to 0.991 [95% confidence interval 0.972–0.989]) and CSF Aβ42/Aβ40 (AUCs 0.961 [95% confidence interval 0.939–0.983] to 0.971 [95% confidence interval 0.949–0.981]) used as standards of truth (figure 3), with no significant difference found between AUC values. Similar findings were obtained for AD dementia cases (figure e-3; doi:10.5061/dryad.2547d7wnf).

In the [18F]flutemetamol end-of-life cohort, we found that both Aβ index and SUVR could predict abnormal Bielschowsky silver stain scores (AUCs 0.820 [95% confidence interval 0.716–0.923] to 0.823 [95% confidence interval 0.725–0.921]) and visual read outcomes (AUCs 0.938 [95% confidence interval 0.889–0.984] to 0.949 [95% confidence interval, 0.911–0.988]) (figure 4), with no significant difference found between AUC values. With the Aβ phases (Thal et al.26) as neuropathologic readout, a similar distribution was seen for [18F]flutemetamol Aβ index and SUVR across Aβ phases (figure 4). Comparison of SUVR and Aβ index measures between Aβ phases (i.e., phase 1 vs 2, 2 vs 3, 3 vs 4, and 4 vs 5) showed significant differences for both measures between phases for the contrasts phase 3 vs 4 (SUVR and Aβ index, p < 0.001) and phase 4 vs 5 (SUVR and Aβ index, p < 0.01).

Finally, we studied whether a combination of Aβ index and visual read was superior to visual read alone. Compared to the binary logistic regression model using only visual read as a predictor, the addition of the Aβ index resulted in a significant increase in AUC (Aβ status as outcome) using CSF Aβ42/ Aβ40 (BioFINDER 0.868 [95% confidence interval 0.843 to 0.894] vs 0.962 [95% confidence interval 0.932–0.987], p < 0.001; ADNI 0.881 [95% confidence interval 0.856–0.906] vs 0.943 [95% confidence interval 0.923–0.962], p < 0.001) and Bielschowsky histopathology (0.910 [95% confidence interval 0.894–0.923] vs 0.962 [95% confidence interval 0.932–0.987], p < 0.001).

Figure 1 Flow diagram providing an overview of the MRI-free normalization method

Shown are the steps required to generate the adaptive template and to spatially normalize the input β-amyloid (Aβ)-PET image. In the upper right corner, the role of the Aβ index is illustrated: the first principal component image is combined with a weighted version of the second component image, yielding a template image optimal for the input image.
Discussion

The objective of the present study was to assess the relationship between Aβ index and Aβ-PET SUVR, including a comparison of the ability of both measures to differentiate between participants on the basis of their Aβ status, using several standards of truth (visual read, CSF Aβ42/Aβ40, and postmortem Aβ histopathology). First, using both [18F]flutemetamol and [18F]florbetapir, we showed that the principal component–based approach to normalization was precise and accurate, with SUVRs from this approach correlating highly with those derived from the MRI-based method in SPM. Using this PET-driven approach, we then showed a close correspondence between the Aβ index and SUVR, with both measures performing equally well in identifying Aβ-positive cases and showing a similar pattern of increase across postmortem Aβ phases. Finally, we showed that the addition of the Aβ index improved prediction of Aβ status relative to the use of visual read alone.

Given recent evidence showing that Aβ-PET imaging led to changes in the clinical management of CI individuals, the importance of accurate and reproducible Aβ image interpretation is clear. Although the visual assessment of Aβ scans as positive or negative has been shown to be an

Figure 2 Scatterplots showing the relationship between Aβ index and SUVR

The association between β-amyloid (Aβ) index and standardized uptake values ratio (SUVR) is shown for [18F]flutemetamol (BioFINDER cohort; A and C) and [18F]florbetapir (Alzheimer’s Disease Neuroimaging Initiative [ADNI] cohort; B and D) PET, with Aβ status defined using (A and B) visual read and (C and D) CSF Aβ42/Aβ40 as standards of truth for Aβ status. CI = cognitively impaired; CU = cognitively unimpaired.
adequately sensitive method with respect to postmortem estimates of plaque burden, studies have shown significant variability across readers.29,30 Findings from several studies indicate that use of quantification could prove a helpful adjunct to visual interpretation,31–34 similar to other areas of nuclear medicine involving PET imaging.35,36 Quantification of Aβ-PET images using SUVR derived from commercial software packages, for instance, has been shown to improve the accuracy of visual reads in clinically relevant cases. This was also the case in the present study, in which the addition of the Aβ index improved prediction of histopathology based Aβ status. The addition of an objective measure such as Aβ index or SUVR will probably be even more important in clinical practice, where many readers are not as experienced as those evaluating clinical PET images in academic research studies or clinical trials. The Aβ index, along with a cutoff indicating whether the scan is positive, could easily be incorporated into currently available commercial software. Quantification has also been shown to result in more consistent detection of early Aβ plaque pathology in CU older adults.40 This finding in particular is of importance given that CU older individuals who are accumulating Aβ in the Aβ-negative range, where visual read alone is likely to prove insensitive, may prove a key target population for anti-Aβ clinical trials.40

A fundamental step prerequisite to quantification in PET is the spatial transformation of data into a common space (i.e., spatial normalization). SUVR values derived with the proposed principal component method were tightly

---

**Figure 3** Receiver operating characteristic plots using Aβ index and SUVR

![ROC plots](image)

Receiver operating characteristic plots for [18F]flutemetamol (BioFINDER cohort; A and C) and [18F]florbetapir (Alzheimer’s Disease Neuroimaging Initiative [ADNI cohort]; B and D) for distinguishing β-amyloid (Aβ)-negative and Aβ-positive participants using (A and B) visual read and (C and D) CSF Aβ42/Aβ40 as standards of truth for Aβ status. CI = confidence interval; SUVR = standardized uptake values ratio.
correlated to those based on the dual-scan (MRI, PET) MRI-driven approach used in SPM, indicating that accurate spatial normalization was achieved. Furthermore, this method removes the need for a separate MRI scan; this is a highly desirable quality given that MRI is not always available as part of routine clinical workup and can be complicated by high rates of nonparticipation due to difficulty lying still during the examination, claustrophobia, contraindications such as pacemakers or metallic implants, and other reasons. In addition, removing the need for MRI would decrease the burden placed on patients and caregivers, and a short CT scan is often adequate to exclude secondary causes of cognitive impairment such as subdural hematoma and tumors and can be done in conjunction with the PET scan. In terms of clinical translation, additional studies are required to address whether the improvements in interreader agreement seen when SUVR is added to visual read of Aβ-PET images are also observed when the Aβ index is used.

In both BioFINDER and ADNI, a range of Aβ index values were observed for a given SUVR level. Despite identical SUVR levels, interpreted as indicating no difference in overall brain Aβ load, differences in the topography of Aβ pathology can be seen between participants. These interparticipant differences may explain the variability seen in Aβ index for a given SUVR value. Although Aβ index as a global metric of Aβ pathology may be of greatest interest from a clinical standpoint, further work addressing whether Aβ index can in fact also provide information about Aβ pathology within different brain regions may be of interest, particularly with respect to the validation of PET-based Aβ staging schemes and with an eye to testing this approach with tau PET. However, the finding that Aβ index values were only significantly different between advanced Aβ phases (3 vs 4 and 4 vs 5), as for SUVR, is in line with earlier work showing that [18F]flutemetamol PET detects Aβ pathology primarily in cases with advanced plaque pathology (i.e., Aβ phase ≥4).

Figure 4 Findings from the [18F]flutemetamol phase 3 end-of-life cohort

Receiver operating characteristic plots (A–D) for distinguishing β-amyloid (Aβ)-negative and Aβ-positive participants using the Bielschowsky silver stain score and visual read are shown in panels A and B, respectively. CI = confidence interval; SUVR = standardized uptake values ratio.

Neurology.org/N Neurology | Volume 95, Number 21 | November 24, 2020 e2841
Two previous studies have used adaptive\textsuperscript{24} and principal component--derived templates\textsuperscript{44} with Aβ-PET. In the first study\textsuperscript{24} using [\textsuperscript{18}F]flumetamol PET, intercept and slope images were generated using linear regression; the slope image in combination with a weight is then used to generate a template. While the slope image is similar to our second principal component image, the principal component--derived template appeared to provide greater accuracy.\textsuperscript{7} In the second study\textsuperscript{44} an adaptive template was generated with [\textsuperscript{11}C]-Pittsburgh compound B and spline-based transformations for the normalization step; due to the use of splines, however, the computational time of their approach exceeds 6 hours, in contrast to an average processing time of \textpm20 seconds per participant with our method. Furthermore, a novel measure called Aβ load (Aβ\textsubscript{L}) was recently presented.\textsuperscript{24} A metric of global Aβ burden, Aβ\textsubscript{L}, is calculated as a linear combination of 2 canonical images (nonspecific binding and a carrying capacity image representing the maximum possible concentration of Aβ).\textsuperscript{45} Although these images and Aβ\textsubscript{L} are conceptually similar to our principal component images and Aβ index, respectively, in contrast to the Aβ\textsubscript{L} method\textsuperscript{45} our method does not require the use of MRI and is several orders of magnitude faster from a per-participant computational standpoint.

Due to variability in the acquisition windows used for scanning, analysis methods, and ROI selection, quantitatively expressed Aβ-PET outcome data cannot currently be directly compared. In an attempt to address this, a method was proposed whereby Aβ-PET values are standardized to a 100-point scale using a linear scaling procedure. The units of this scale are called Centiloids, with 0 representing the average uptake in Aβ-negative participants and 100 representing the average in patients with mild to moderate AD.\textsuperscript{18} While the Aβ index could be converted to Centiloids via the prescribed steps, the fact that it is independent of ROI definition suggests that it could be directly comparable between Aβ-PET tracers, without the need for conversion to the Centiloid scale. This would require, however, that a universal adaptive template be established by applying a principal component--based analysis to a dataset comprising existing commercial Aβ-PET tracers. Future work is required to explore this possibility.

Strengths of the present study include the use of 2 different Aβ-PET tracers across 3 independent cohorts, a large sample size, and the use of multiple standards of truth for defining Aβ-status. Certain limitations apply as well, however. First, cases of AD dementia or non-AD neurodegenerative disorders were not included. The close association of Aβ index to SUVR across a range of values, however, indicates that the relationship between these metrics is governed by brain Aβ levels and is therefore independent of clinical diagnosis. Therefore, omitting these diagnostic groups is unlikely to have affected our results. Second, the patients in the Swedish BioFINDER study have been recruited in a consecutive fashion at 3 different memory clinics, with \textpm90\% of these referred by primary care physicians. In the ADNI study, the patients were recruited from many different clinics and thereby represent a more selected sample. Still, the results obtained for the Aβ-PET pathology accumulation index in both these studies are very similar. In light of findings showing that clinic-based cohorts such as ADNI and, to a lesser extent, BioFINDER might have a lower prevalence of infarcts and mixed pathologies,\textsuperscript{46} further studies are required to validate the use of Aβ index in community-based cohorts. Third, we did not examine the effect of atrophy on Aβ and SUVR. Because neurodegenerative disorders such as AD are accompanied by progressive cortical atrophy, susceptibility to partial volume effects increases, which, in the case of Aβ-PET, can diminish estimates of tracer retention. While partial volume effects were likely present to some degree in the BioFINDER and ADNI cohorts, the strong correlation between Aβ index and SUVR across participants suggests that these metrics were not differentially affected. We cannot exclude, however, that the strength of the association between Aβ index and SUVR may be affected by atrophy in individual cases. Although fully quantitative measures (i.e., binding potential or distribution volume ratio) would have been preferable over the use of SUV—due the sensitivity of SUVR to cerebral blood flow–induced changes in tracer kinetics\textsuperscript{47}—binding potential and distribution volume ratio require the use of dynamic data, which were not available. Lastly, in addition to the lack of antemortem diagnosis (beyond the presence or absence of dementia), there was considerable variation in the PET to postmortem delay (scan-to-death time interval) in the end-of-life cohort; although this may have resulted in changes in Aβ burden not captured by the initial [\textsuperscript{18}F]flumetamol studies, our findings with the Aβ phases and prior work showing that the PET-to-death time interval did not affect the diagnostic performance of [\textsuperscript{18}F]flumetamol\textsuperscript{48} argue against this being the case.

Although the proposed Aβ index showed a tight association to SUVR values and similar discriminative and predictive performance, it carries an advantage over SUVR in that it does not require the definition of target and reference regions. The Aβ index may therefore prove simpler to implement in clinical settings. Further work is needed to address whether the Aβ index could be implemented as a common measure across different Aβ tracers and analytical approaches, without the need for standardization to the Centiloid scale. An Aβ index–driven approach would require the availability of a hybrid template derived from all 3 commercially available Aβ tracers. This template is under development and will be the focus of future work.

**Study funding**

Work at the authors’ research center was supported by the European Research Council, the Research Foundation Flanders (grant G0F8516N), the Swedish Research Council, the Knut and Alice Wallenberg Foundation, the Marianne and Marcus Wallenberg Foundation, the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s disease) at Lund University, the Swedish Alzheimer Foundation, the Swedish Brain Foundation, the Parkinson Foundation of Sweden, the Parkinson Research Foundation, the Skåne
University Hospital Foundation, the Bundy Academy, and the Swedish federal government under the ALF agreement.

Disclosure
Antoine Leuzy reports no disclosures. Johan Lilja is a former employee of GE Healthcare and current employee of Hermes Medical Solutions AB, Stockholm, Sweden. Christopher J. Buckley is a current employee of GE Healthcare. Rik Ossenkoppele and Sebastian Palmqvist report no disclosures. Christopher J. Buckley, Mark Battle, and Gill Farrar are current employees of GE Healthcare. Dietmar R. Thal, Shorena Janelidze, Erik Stromrud, and Ruben Smith report no disclosures. Oskar Hansson has acquired research support (for the institution) from Roche, Pfizer, GE Healthcare, Biogen, AVID Radiopharmaceuticals, and Euroimmun. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Biogen and Roche. Go to Neurology.org/N for full disclosures.

Publication history
Received by Neurology February 11, 2020. Accepted in final form August 3, 2020.

Appendix Authors

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antoine Leuzy, PhD</td>
<td>Lund University, Malmö, Sweden</td>
<td>Design and conceptualized study; analyzed the data; performed the statistical analyses; drafted the manuscript for intellectual content</td>
</tr>
<tr>
<td>Johan Lilja, PhD</td>
<td>Lund University, Malmö, Sweden</td>
<td>Design and conceptualized study; analyzed the data; drafted the manuscript for intellectual content</td>
</tr>
<tr>
<td>Christopher J. Buckley, PhD</td>
<td>GE Healthcare Life Sciences, Amersham, UK</td>
<td>Design and conceptualized study; analyzed the data; drafted the manuscript for intellectual content</td>
</tr>
<tr>
<td>Rik Ossenkoppele, PhD</td>
<td>Lund University, Malmö, Sweden; VU University Medical Center, Amsterdam, the Netherlands</td>
<td>Major role in the acquisition of data; interpreted the data; revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Sebastian Palmqvist, MD, PhD</td>
<td>Lund University, Malmö, Sweden; Skåne University Hospital, Lund, Sweden</td>
<td>Major role in the acquisition of data; interpreted the data; revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Mark Battle, MSc</td>
<td>GE Healthcare Life Sciences, Amersham, UK</td>
<td>Major role in the acquisition of data; interpreted the data; revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Gill Farrar, PhD</td>
<td>GE Healthcare Life Sciences, Amersham, UK</td>
<td>Major role in the acquisition of data; interpreted the data; revised the manuscript for intellectual content</td>
</tr>
</tbody>
</table>

References


Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load
Antoine Leuzy, Johan Lilja, Christopher J. Buckley, et al.
Neurology 2020;95:e2834-e2844 Published Online before print October 19, 2020
DOI 10.1212/WNL.00000000000011031

This information is current as of October 19, 2020

| Updated Information & Services | including high resolution figures, can be found at: http://n.neurology.org/content/95/21/e2834.full |
| References | This article cites 47 articles, 13 of which you can access for free at: http://n.neurology.org/content/95/21/e2834.full#ref-list-1 |
| Citations | This article has been cited by 1 HighWire-hosted articles: http://n.neurology.org/content/95/21/e2834.full##otherarticles |
| Subspecialty Collections | This article, along with others on similar topics, appears in the following collection(s): Alzheimer's disease http://n.neurology.org/cgi/collection/alzheimers_disease PET http://n.neurology.org/cgi/collection/pet |
| Permissions & Licensing | Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions |
| Reprints | Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise |